Pathogenetic processes

Pathogenetic processes (PPs) — are major molecular and phenotypic characteristics that determinate cancer as complex evolutionary disease process.


Name ( total associations | neutral | plus | minus )


Invasion ( 4761 / 2406 /
801
/
1554
)
migration ( 3887 / 1959 /
653
/
1275
)
colony formation ( 641 / 326 /
87
/
228
)
cell cycle ( 262 / 137 /
46
/
79
)
Proliferation ( 5486 / 2763 /
918
/
1805
)
cell cycle progression ( 195 / 99 /
46
/
50
)
Cell growth ( 960 / 484 /
152
/
324
)
Senescence ( 77 / 42 /
27
/
8
)
cell cycle arrest ( 519 / 263 /
228
/
28
)
MTX resistance ( 3 / 2 /
0
/
1
)
Tomudex (TDX) resistance ( 1 / 1 /
0
/
0
)
Metastasis ( 1403 / 710 /
296
/
397
)
AKT signaling ( 379 / 191 /
62
/
126
)
cisplatin resistance ( 424 / 213 /
73
/
138
)
Autophagy ( 508 / 255 /
116
/
137
)
survival ( 138 / 71 /
24
/
43
)
Apoptosis ( 2307 / 1167 /
744
/
396
)
cell viability ( 380 / 194 /
51
/
135
)
5fluorouracil resistance ( 144 / 81 /
27
/
36
)
G1-S checkpoint ( 7 / 4 /
2
/
1
)
Lung metastasis ( 79 / 41 /
19
/
19
)
DNA repair ( 73 / 37 /
25
/
11
)
TGF-beta signaling ( 478 / 264 /
107
/
107
)
motility ( 227 / 116 /
38
/
73
)
EMT ( 1185 / 599 /
239
/
347
)
stemness ( 319 / 160 /
76
/
83
)
BMP signaling ( 235 / 127 /
72
/
36
)
Hedgehog (Hh) signaling ( 52 / 27 /
9
/
16
)
JAK/STAT signaling ( 128 / 65 /
32
/
31
)
Angiogenesis ( 320 / 165 /
53
/
102
)
growth ( 222 / 131 /
26
/
65
)
tumor-initiating properties ( 9 / 6 /
0
/
3
)
tumor growth ( 1116 / 561 /
191
/
364
)
Chemoresistance ( 326 / 164 /
63
/
99
)
Paclitaxel resistance ( 97 / 49 /
17
/
31
)
WNT signaling ( 490 / 246 /
109
/
135
)
beta-catenin signaling ( 85 / 43 /
14
/
28
)
Brain metastasis ( 2 / 1 /
0
/
1
)
docetaxel resistance ( 59 / 31 /
21
/
7
)
cyclophosphamide sensitivity ( 1 / 1 /
0
/
0
)
doxorubicin resistance ( 99 / 50 /
16
/
33
)
recurrence ( 2 / 2 /
0
/
0
)
adhesion ( 57 / 31 /
8
/
18
)
NF-kB signaling ( 267 / 135 /
67
/
65
)
Antiapoptosis ( 37 / 20 /
12
/
5
)
Oxaliplatin resistance ( 33 / 17 /
7
/
9
)
Anoikis ( 36 / 19 /
9
/
8
)
MET ( 20 / 11 /
9
/
0
)
differentiation ( 95 / 48 /
31
/
16
)
Tamoxifen resistance ( 25 / 13 /
8
/
4
)
Radioresistance ( 169 / 86 /
32
/
51
)
inflammation ( 119 / 60 /
26
/
33
)
redox homeostasis ( 3 / 3 /
0
/
0
)
Sorafenib resistance ( 44 / 22 /
6
/
16
)
tumor progression ( 82 / 42 /
24
/
16
)
aerobic glycolysis ( 87 / 44 /
13
/
30
)
ER stress ( 32 / 17 /
0
/
15
)
Oxaliplatin ( 2 / 1 /
1
/
0
)
cellular repair of DNA double-strand breaks ( 1 / 1 /
0
/
0
)
etoposide ( 9 / 5 /
3
/
1
)
RAS signaling pathway ( 10 / 6 /
2
/
2
)
multidrug resistance ( 22 / 12 /
5
/
5
)
ERK pathway (MAPK pathway) ( 225 / 113 /
36
/
76
)
Liver metastasis ( 32 / 18 /
6
/
8
)
scattering ( 1 / 1 /
0
/
0
)
HCPT (Hydroxycamptothecin) resistantance ( 1 / 1 /
0
/
0
)
cell polarity ( 1 / 1 /
0
/
0
)
cell spreading ( 8 / 6 /
0
/
2
)
Temozolomide (TMZ) resistance ( 42 / 21 /
6
/
15
)
cancer progression ( 16 / 9 /
5
/
2
)
PI3K signaling ( 131 / 66 /
23
/
42
)
inflammatory monocyte recruitment ( 4 / 3 /
0
/
1
)
erythropoiesis ( 3 / 3 /
0
/
0
)
NK cell cytotoxicity ( 6 / 4 /
0
/
2
)
Response to genotoxic stress ( 6 / 4 /
2
/
0
)
mitoxantrone (MX) Resistance ( 1 / 1 /
0
/
0
)
Castrate Resistance ( 31 / 18 /
10
/
3
)
Bone metastasis ( 28 / 16 /
4
/
8
)
anchorage-independent growth ( 47 / 24 /
13
/
10
)
Camptothecin resistance ( 3 / 2 /
0
/
1
)
macrophage attraction ( 1 / 1 /
0
/
0
)
tumor-stroma interactions ( 3 / 2 /
1
/
0
)
Imatinib resistance ( 20 / 12 /
0
/
8
)
myeloid differentiation ( 27 / 14 /
7
/
6
)
microtubule-targeting drugs ( 4 / 4 /
0
/
0
)
disease-free survival ( 3 / 2 /
0
/
1
)
epirubicin resistance ( 5 / 3 /
2
/
0
)
Transformation ( 15 / 12 /
2
/
1
)
neutrophil chemotaxis ( 2 / 2 /
0
/
0
)
NOTCH signaling ( 97 / 49 /
24
/
24
)
gefitinib resistance ( 40 / 21 /
6
/
13
)
Hepatocyte differentation ( 2 / 2 /
0
/
0
)
poor prognosis ( 46 / 26 /
17
/
3
)
unfolded protein response ( 7 / 5 /
1
/
1
)
P38 signaling ( 39 / 20 /
11
/
8
)
Vorinostat Resistance ( 6 / 4 /
2
/
0
)
Osteolysis ( 5 / 3 /
0
/
2
)
EGFR-TKI resistance ( 4 / 3 /
0
/
1
)
Tumorigenesis ( 43 / 22 /
7
/
14
)
Adriamycin (Adr) resistance ( 30 / 16 /
4
/
10
)
lipogenesis ( 25 / 13 /
1
/
11
)
mTOR signaling ( 100 / 50 /
13
/
37
)
cytotoxicity ( 2 / 1 /
1
/
0
)
gluconeogenesis ( 6 / 3 /
1
/
2
)
chondrogenesis ( 1 / 1 /
0
/
0
)
Lapatinib resistance ( 6 / 3 /
1
/
2
)
Neratinib resistance ( 2 / 1 /
0
/
1
)
Afatinib resistance ( 2 / 1 /
0
/
1
)
daunorubicin (DNR) Resistance ( 8 / 4 /
2
/
2
)
Response to oxidative stress ( 14 / 13 /
1
/
0
)
T cell activation ( 3 / 2 /
1
/
0
)
gemcitabine resistance ( 68 / 34 /
12
/
22
)
genomic instability ( 14 / 7 /
3
/
4
)
glycolysis ( 19 / 16 /
0
/
3
)
insulin signaling ( 1 / 1 /
0
/
0
)
endothelial-mesenchymal transition ( 1 / 1 /
0
/
0
)
branching-morphogenesis ( 1 / 1 /
0
/
0
)
Taxanes (paclitaxel and docetaxel) resistance ( 22 / 14 /
5
/
3
)
Vinblastine (Velban) resistance ( 1 / 1 /
0
/
0
)
Hippo signaling pathway ( 184 / 92 /
68
/
24
)
glucose metabolism ( 20 / 10 /
3
/
7
)
BRCAness ( 2 / 1 /
1
/
0
)
BRAFi resistance ( 4 / 2 /
1
/
1
)
MEKi resistance ( 4 / 2 /
1
/
1
)
immunoevasion ( 40 / 20 /
13
/
7
)
MAPK/JNK Signaling Pathway ( 26 / 13 /
5
/
8
)
Hypoxic response ( 14 / 8 /
6
/
0
)
carboplatin resistance ( 6 / 3 /
1
/
2
)
Trastuzumab resistance ( 20 / 10 /
6
/
4
)
fibrosis ( 54 / 27 /
12
/
15
)
TRAIL resistance ( 16 / 8 /
5
/
3
)
Rapamycin resistance ( 2 / 1 /
0
/
1
)
Cetuximab resistance ( 20 / 10 /
7
/
3
)
BCL2 inhibitors resistance ( 2 / 1 /
0
/
1
)
Necrosis ( 6 / 3 /
2
/
1
)
pyroptosis ( 16 / 8 /
7
/
1
)
Sunitinib resistance ( 10 / 5 /
5
/
0
)
Tyrosine kinase inhibitors (TKIs) resistance ( 1 / 1 /
0
/
0
)
IFN production ( 10 / 5 /
2
/
3
)
Antiviral response ( 13 / 7 /
2
/
4
)
Ibrutinib resistance ( 1 / 1 /
0
/
0
)